Page 52 - 台灣肝癌醫學冬季會手冊-1222-V3_Neat

Factors predicting outcomes of hepatitis B-related cirrhosis patients

with long-term antiviral therapy

1,
1
1
3
2
1
Yi-Lin Chen , Chih-Lin Lin , Kuo-Chih Tseng, Kuan-Yang Chen, Li-Ying Liao, Jia-Horng Kao
1 Department of Gastroenterology, Taipei City Hospital, Ren-Ai branch, Taipei, Taiwan.
2 Department of Internal Medicine, Dalin Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation,
Chia-Yi; School of Medicine, Tzuchi University, Hualien, Taiwan

3 Division of Gastroenterology and Hepatology, Department of Internal Medicine, National Taiwan

University Hospital, Taipei, Taiwan.

Key words: decompensated cirrhosis, hepatitis B virus, hepatocellular carcinoma, nucleos(t)ide

analogue

Abstract

Background and aims:

Long-term nucleos(t)ide analogues (NA) therapy has been shown to improve the survival in patients

with HBV-related cirrhosis. The aim of this study was to evaluate the clinical outcomes and factors

associated with survival in HBV-related cirrhotic patients receiving long-term NA treatment. In

addition, the impact of HCC development on the survival of HBV-related cirrhotic patients with

antiviral therapy was also examined.

Methods:

A total of 126 HBV-related cirrhosis, treatment naive patients with serum levels of HBV DNA more

than 2000 IU, including 67 compensated cirrhosis and 59 decompensated cirrhosis, were

retrospectively enrolled. Patients who had hepatitis C or D virus, or human immunodeficiency virus

co-infection, had a history of heavy alcohol use, had hepatocellular carcinoma and other causes of

liver disease were also excluded from this study. The effectiveness of treatment, survival and risk

factors of mortality were determined. Baseline data of biochemical tests were collected before the